Bioenvision, Genzyme disagree on Clofarabine pact rights

(Reuters) - Genzyme, which has agreed to acquire Bioenvision,
co-develops Clofarabine and markets it in the Unites States and
Canada. Bioenvision markets the product in Europe.





Read more at Reuters.com Bonds News